Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
AnaptysBio has not specified the timing of its Q2 2026 earnings release, making it difficult to interpret whether Day 0 moves reflect anticipation or immediate reaction.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-12 | -$2.34 (-3.45%) | $5.84 (8.61%) | -$2.89 (-4.41%) | $7.25 (11.06%) |
| 2026-03-03 | -$1.39 (-3.79%) | $1.37 (3.75%) | +$5.15 (+14.61%) | $5.68 (16.12%) |
| 2025-11-04 | -$0.87 (-3.61%) | $1.27 (5.27%) | +$0.84 (+3.63%) | $3.71 (16.03%) |
| 2025-08-06 | -$0.77 (-4.85%) | $1.02 (6.48%) | -$1.45 (-9.63%) | $2.27 (15.13%) |
| 2025-05-05 | -$0.31 (-2.17%) | $0.55 (3.92%) | -$0.41 (-2.94%) | $1.05 (7.62%) |
| 2025-02-27 | -$0.40 (-3.53%) | $0.79 (7.00%) | +$0.28 (+2.56%) | $2.48 (22.68%) |
| 2024-11-05 | -$0.04 (-0.30%) | $0.62 (4.66%) | +$1.55 (+11.72%) | $1.40 (10.56%) |
| 2024-08-05 | -$0.26 (-1.19%) | $1.09 (4.98%) | -$0.19 (-0.90%) | $1.32 (6.12%) |
| Avg Abs Move | 2.86% | 5.58% | 6.30% | 13.16% |
Historical price behavior around earnings shows average absolute moves of 2.86% on Day 0 and 6.30% on Day +1, with Day +1 ranges averaging 13.16%, indicating significant volatility in the session following results. The most recent earnings release on May 12, 2026, saw the stock decline 3.45% on Day 0 and extend losses to 4.41% by Day +1, consistent with the magnitude of the earnings miss. The March 3, 2026 report produced the strongest positive reaction, with the stock surging 14.61% on Day +1 following a substantial earnings beat. Notably, the stock has shown a tendency for larger moves on Day +1 than Day 0 across most reports, suggesting that investors often need time to digest the results and management commentary before the full reaction materializes. With the stock's average Day +1 range exceeding 13%, options traders and investors should prepare for potentially significant price swings in the session following this release.
Part 3: What Analysts Are Saying
Analyst sentiment on AnaptysBio remains overwhelmingly bullish, with the stock carrying an average recommendation of 4.83 out of 5.0—firmly in Strong Buy territory. The current consensus includes 11 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings among the 12 analysts covering the stock. This represents unchanged sentiment compared to one month ago, indicating that the Q1 earnings miss has not materially altered the Street's long-term conviction in the company's prospects.
The average price target of $87.09 implies 47.6% upside from the current price of $58.98, reflecting substantial optimism about the company's pipeline value and commercial potential. However, the wide range of price targets—from a low of $70.00 to a high of $140.00—reveals significant disagreement among analysts about the appropriate valuation, with the high-end estimate implying more than double the upside of the low-end target. This dispersion suggests that while analysts are uniformly positive on the direction, there is considerable uncertainty about the magnitude and timing of value realization.
Part 4: Technical Picture
The Barchart Technical Opinion for AnaptysBio currently stands at 56% Buy, unchanged from last week but improved from 40% Buy one month ago, indicating a gradual strengthening of technical momentum heading into earnings. The stock is trading at $58.98, positioned above all major moving averages—the 5-day ($58.03), 10-day ($56.99), 20-day ($55.33), 50-day ($57.97), 100-day ($56.20), and 200-day ($44.25)—a bullish configuration that suggests the stock has established a solid technical foundation.
Timeframe Analysis:
- Short-term (Hold): Neutral signal suggests near-term momentum has paused after recent gains, indicating potential consolidation
- Medium-term (100% Buy): Strong buy signal reflects positive intermediate-term trend momentum supporting the current rally
- Long-term (100% Buy): Strong buy signal indicates the longer-term trend remains firmly positive, with the stock well above its 200-day moving average
Trend Characteristics: The combination of Soft strength and Average direction suggests the stock is in a constructive but not overheated uptrend, providing a relatively neutral technical backdrop for the earnings event.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $58.03 | 50-Day MA | $57.97 |
| 10-Day MA | $56.99 | 100-Day MA | $56.20 |
| 20-Day MA | $55.33 | 200-Day MA | $44.25 |
The stock's position above all key moving averages, particularly its 33.3% premium to the 200-day moving average at $44.25, indicates strong long-term momentum that could provide support if earnings disappoint. However, the stock's proximity to its 50-day moving average ($57.97) suggests limited near-term cushion, and a negative earnings surprise could quickly push the stock back toward this key support level. The technical setup is moderately supportive heading into earnings, with the uptrend intact but momentum indicators suggesting the stock may need a positive catalyst to extend gains. Given the average post-earnings move of 6.30% and the stock's recent volatility, traders should be prepared for a test of either the $55 support zone (20-day moving average) on disappointment or a breakout toward the $65-70 range on a positive surprise.